**Financial Highlights:** Innova Captab's Q1 FY26 revenue rose 19% YoY to ₹351.5 Cr.

EBITDA jumped 28% to ₹56.6 Cr (16.1% margin). PAT grew 5% to ₹31.0 Cr (8.8% margin), impacted by higher depreciation/finance costs.

CDMO revenue (71% of total) grew 8%, while Branded Generics soared 59%. Exports accounted for 70% of total revenue. **Strategic Initiatives & Growth Drivers:** The company reorganized into focused CDMO and Branded Generics verticals.

Its new Jammu facility (commercialized Jan 2025) is gaining momentum, poised for significant ramp-up with government incentives.

Capacity expansion, new product development, and R&D are key growth drivers. **Business Developments:** Recent developments include the acquisition of Sharon Bio-Medicine and the commercialization of the advanced Jammu plant.

Innova Captab now holds the third-largest finished tablet/capsule manufacturing capacity in India, fueling growth through client engagement and market expansion. **Market Position & Competitive Advantage:** A preferred CDMO partner, Innova Captab boasts a strong global branded generics presence (60+ countries, 3,700+ products, 2.2 lakh+ India touchpoints). Its comprehensive model, expanding manufacturing base, and R&D focus highlight its competitive edge. **Investor Implications:** These updates signal positive growth potential.

Solid Q1 performance, strategic reorganization, and the new facility's ramp-up suggest a strong trajectory.

Despite short-term cost impacts on PAT, underlying operational strength and strategic execution promise long-term value.